Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CTSA | P10619 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | LAP3 | P28838 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8866823 | 0.81 | CTSA (0.39) | TDP1TSHRCTSAACHEKDM4E | |
| SCHEMBL28982528 | 0.79 | CTSA (0.37) | TDP1CTSAACHEKDM4EALDH1A1 | |
| SCHEMBL21685554 | 0.79 | CTSA (0.37) | TDP1CTSAACHEKDM4EALDH1A1 | |
| SCHEMBL8715424 | 0.77 | LMNA (0.39) | TDP1LMNATSHRCTSAACHE | |
| SCHEMBL2717779 | 0.77 | POLB (0.40) | TDP1MEN1TSHRKMT2ACTSA | |
| SCHEMBL18985287 | 0.77 | GABRP (0.37) | TDP1CTSAACHEKDM4EALDH1A1 | |
| SCHEMBL21684894 | 0.76 | CTSA (0.34) | TDP1MEN1KMT2ACTSAACHE | |
| SCHEMBL11740118 | 0.74 | CTSA (0.37) | TSHRCTSAACHEKDM4EALDH1A1 | |
| SCHEMBL2720165 | 0.74 | MGAM (0.43) | TDP1LMNATSHRCTSAACHE | |
| SCHEMBL29027239 | 0.73 | MEN1 (0.37) | TDP1MEN1LMNAHPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6284910-B1 | FARNESYL TRANSFERASE INHIBITORS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2001-09-04 | — | — | US | claimed |
| EP-4219460-B1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA INC (US) | 2025-02-26 | — | — | EP | disclosed |
| US-20250011324-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA, INC., | 2025-01-09 | — | — | US | disclosed |
| US-12152026-B2 | Transglutaminase 2 (TG2) inhibitors | SITARI PHARMA, INC. (US) | 2024-11-26 | — | — | US | disclosed |
| EP-4219460-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | Sitari Pharma, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-3833348-B1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA INC (US) | 2023-05-31 | — | — | EP | disclosed |
| US-11548892-B1 | Transglutaminase 2 (TG2) inhibitors | SITARI PHARMA, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| EP-3833348-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA, INC (US) | 2021-06-16 | — | — | EP | disclosed |
| US-20210163480-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA, INC. | 2021-06-03 | — | — | US | disclosed |
| CN-112789040-A | Transglutaminase 2(TG2) inhibitors | 思达利医药公司 | 2021-05-11 | — | — | CN | disclosed |
| WO-2020033784-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA, INC. (US) | 2020-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163480-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | TGM2, TGM3, TGM1 | TDP1 1246/4885MEN1 3008/4885LMNA 3679/4885 |
| US-11548892-B1 | Transglutaminase 2 (TG2) inhibitors | TGM2, TGM3, TGM1 | TDP1 1246/4885MEN1 3008/4885LMNA 3679/4885 |
| US-12152026-B2 | Transglutaminase 2 (TG2) inhibitors | TGM2, TGM3, TGM1 | TDP1 1246/4885MEN1 3008/4885LMNA 3679/4885 |
| US-20250011324-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | TGM2, TGM3, TGM1 | TDP1 1246/4885MEN1 3008/4885LMNA 3679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.